相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
4
100.0%
暂无批准数据
- Phase III protocols now collect roughly 5.9 million data points on average, with data volume growing about 11% annually since 2020, making uniform oversight models progressively less effective. - ICH E6(R3) and FDA and MHRA guidance now call for quality-by-design, critical-to-quality factors and risk-proportionate monitoring instead of routine 100% source data verification. - An analysis of 18 oncology trials estimated trial-level returns on RBQM investment of six to 23 times, driven largely by 8% to 19% reductions in clinical-phase duration. - In 1,111 sites across 159 trials, 83% of sites flagged as at-risk by central statistical monitoring improved on predefined quality metrics after targeted investigation and follow-up.
- The global pharmaceutical industry has committed an additional £2 billion of investment into the UK since September 2025, spanning AI-enabled discovery science to large-scale medicines manufacturing. - The ABPI's 2026 Competitiveness Report finds the UK has begun reversing years of decline, driven by policy commitments including a raised NICE cost-effectiveness threshold and a pledge to invest 0.6% of GDP in innovative medicines. - Sustained delivery of government commitments will determine whether the recovery holds, with the potential to create up to 81,300 new jobs and £33.4 billion in direct GVA by 2035. - Key risks remain, including the UK's last-place ranking for adoption of new medicines, high clawback rates, and a 25% decline in clinical trial recruitment between 2022/23 and 2024/25.
- A major 2022 analysis of 76 trials and over 103,000 patients found GLP-1 users were 37 percent more likely to develop gallbladder or bile duct problems. - NHS gallbladder operations reached 80,196 in 2024-25, the highest in a decade and a 15 percent rise year on year, with surgeons reporting weekly GLP-1 cases. - Retatrutide, an unapproved triple-agonist peptide, is being sold illegally online as a 'research chemical' while still in phase 3 trials. - Eli Lilly plans to seek regulatory review of retatrutide in early 2027, but experts warn unregulated supplies carry dosing, purity and infection risks.
- A comprehensive 25-year analysis of ClinicalTrials.gov data reveals UK oncology trial activity peaked at 333 studies in 2017 before declining, with a partial recovery to 214 trials by 2025. - Population-adjusted trial density in the UK (18.2 trials per million, 2021–2025) remains intermediate between high-intensity regions like the EU (28.6) and the USA (28.3) and emerging China (6.3). - The UK's new Clinical Trials Regulation, effective 28 April 2026, introduces risk-proportionate frameworks and a 150-day target from regulatory submission to first patient recruitment. - Commercial trials have shown greater resilience post-COVID-19, while non-commercial trial numbers continue to decline, reflecting shifting funding dynamics within the UK research ecosystem.
- The convergence of iPSCs, organoids, organs-on-chips, and AI is driving a fundamental shift away from animal models toward human-relevant drug development platforms. - Regulatory milestones including the FDA Modernization Act 2.0 (2022) and recent NMPA acceptance of validated NAMs are creating global momentum for non-animal methods. - iPSC-derived models combined with CRISPR gene editing enable scalable, genetically defined human cell assays that capture patient-specific disease mutations and diverse genotypes. - Key challenges remain, including incomplete tissue complexity, lack of global regulatory harmonization, and the need for rigorous validation against historical animal and clinical data.
- Sophie Robert, a senior staff nurse at Princess Elizabeth Hospital, is calling for mandatory medicine safety training for healthcare workers after witnessing gaps in adverse drug reaction identification and reporting. - The UK's MHRA received 40,935 spontaneous suspected ADR reports in 2020, yet no reliable figures exist for Guernsey, highlighting significant data gaps in the region. - Dr Linda Härmark of the Drug Safety Research Unit emphasized that public awareness of the Yellow Card reporting system remains "generally quite low" and that reporting can help prevent harm to others. - Robert met with Guernsey's Committee for Health and Social Care, describing discussions as "open and positive," and stressed that medicine safety should be "a real top priority."
- The UK MHRA is strengthening safety warnings for all botulinum toxin type A products following reports of rare but potentially life-threatening cases of iatrogenic botulism. - Symptoms including difficulty swallowing, slurred speech, breathing difficulties, and muscle weakness can develop within days or up to four weeks after treatment. - The risk of adverse reactions is higher in patients with underlying neurological disorders, when high doses are used, or when products are used off-label or from unlicensed sources. - The MHRA's Criminal Enforcement Unit has launched investigations linked to unlicensed botulinum toxin products following a spike in hospital admissions.
- The DHSC has issued a tier two medicine supply notification for nifedipine modified-release tablets across multiple strengths, with several brands out of stock through late 2026. - Tensipine MR, Dexipress MR, Adalat LA, and Neozipine XL brands face shortages, while Adanif XL has been discontinued; alternative brands and Coracten capsules remain available. - A separate DHSC notification warns that Viatris-manufactured oxcarbazepine 150mg tablets are out of stock until mid-July 2026, with Novartis's Trileptal available to meet demand. - Nifedipine is a calcium-channel blocker for hypertension, angina, and Raynaud's; oxcarbazepine is an anticonvulsant used to control seizures in epilepsy patients.
- AMO Pharma reached agreement with the FDA, MHRA, and Health Canada on the design of a registrational study for AMO-02 (oral tideglusib) in congenital myotonic dystrophy type 1 (cDM1). - The trial will use hospitalization as the primary efficacy endpoint, reflecting the significant burden of this life-threatening rare neuromuscular disorder. - Multiple functional assessments will serve as secondary outcome measures to characterize disease progression and capture the variable clinical features of cDM1. - The company expects to provide an update on study initiation during the third quarter of 2026.
- Contact lenses are classified as medical devices in nearly every regulated market, requiring market-specific registration, certification, and import documentation that differs from country to country. - No single approval is universally recognized: a CE mark does not satisfy the US FDA, an FDA 510(k) does not unlock China, and India runs its own assessment even for products approved in Europe and America. - Most major markets, including the EU, UK, China, Japan, Australia, Canada, India, and South Korea, mandate a local representative, agent, sponsor, or Responsible Person for foreign manufacturers. - Constar (Gansu Constar Technology Group), a China-based OEM/ODM manufacturer, compiled the guide and holds FDA, CE 0197, and ISO 13485 certifications simultaneously, a rare combination among global factories.
